Biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated DNA , both in Circulating Tumor Cells (CTCs) and in plasma (cell free circulating tumor DNA). Our mission is to improve outcomes for cancer patients by advancing oncology diagnostics. We utilize patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. Additionally, we offer services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. Our strategic focus is to promote our unique technology (CEE® cell enrichment and extraction) and family of laboratory tests (OncoCEE™) to the Oncology Community. The CEE® system has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. Examples of these rare cells are circulating tumor cells (CTCs) in patients with early-stage, metastatic or recurrent cancers. Biocept provides products and services to detect and analyze these rare cells in order to provide information that physicians can use to make treatment decisions. We employ our unique laboratory tests through an offering of services to medical/surgical oncologists, pathologists, hospitals, cancer centers, universities, and pharmaceutical/clinical researchers. We believe that our technology saves costs for the healthcare system by reducing the need for re-biopsy or further surgery. Biocept has partnerships with strategic industry leaders as well as major cancer centers.
Company Growth (employees)
San Diego, US
Size (employees)
42 (est)
Biocept was founded in 1993 and is headquartered in San Diego, US

Key People at Biocept

Michael W. Wallace

Michael W. Wallace

President & CEO
Lyle Arnold

Lyle Arnold


Biocept Office Locations

Biocept has an office in San Diego
San Diego, US (HQ)
5810 Nancy Ridge Dr

Biocept Data and Metrics

Biocept Financial Metrics

$, USD

Net income (FY, 2016)

(18.4 m)

Market capitalization (23-Jun-2017)

37.8 m

Closing share price (23-Jun-2017)


Cash (31-Dec-2016)

4.6 m
Biocept's current market capitalization is $37.8 m.
$, USDFY, 2014FY, 2015FY, 2016

Net Income

(15.9 m)(16.9 m)(18.4 m)
$, USDFY, 2014FY, 2015FY, 2016


5.4 m8.8 m4.6 m

Accounts Receivable

10.6 k34.2 k129 k


338.7 k435.9 k484.6 k

Current Assets

5.9 m9.6 m5.8 m

Total Assets

6.6 m10.6 m7.6 m

Accounts Payable

641.4 k632.5 k960.5 k

Current Liabilities

1.4 m3.3 m4.4 m

Additional Paid-in Capital

138.1 m158.9 m174.3 m

Retained Earnings

(138.3 m)(155.2 m)(173.6 m)

Total Equity

658.7 k

Financial Leverage

11.5 x
$, USDFY, 2014FY, 2015FY, 2016

Net Income

(15.9 m)(16.9 m)(18.4 m)

Depreciation and Amortization

251.2 k261.4 k322 k

Accounts Receivable

(1.4 k)(23.6 k)(94.8 k)


(401.4 k)(80.4 k)494.7 k

Accounts Payable

(981.9 k)(51.8 k)332.7 k

Cash From Operating Activities

(14.6 m)(15.2 m)(15.7 m)

Cash From Investing Activities

(394.9 k)(165.2 k)(451.4 k)

Cash From Financing Activities

20.3 m18.8 m11.9 m

Interest Paid

402.1 k405.7 k358.6 k

Income Taxes Paid

8002.2 k2.1 k
Y, 2016

Financial Leverage

11.5 x

Biocept Market Value History

Biocept Online and Social Media Presence

Biocept Company Life and Culture

You may also be interested in